海藻酸钠微球栓塞治疗肝细胞癌患者的近期疗效

Short-term efficacy of embolization with sodium alginate microspheres in patients with hepatocellularcar cinoma

目的探讨海藻酸钠微球(KMG)经肝动脉栓塞治疗肝细胞癌(HCC)的近期临床疗效。方法回顾性分析应用KMG经肝动脉栓塞治疗2009年7月至2012年11月间在我院肝细胞癌治疗的54例HCC患者的临床资料,分析其相关不良反应、并发症及肿瘤的近期疗效。结果所有患者均成功行栓塞治疗,术后不良反应包括:肝区疼痛66.67%(36/54),发热55.56%(30/54),恶心、呕吐27.78%(15/54),无严重并发症发生;22例HCC患者合并肝动脉门静脉分流(APS)或肝动脉肝静脉分流(AVS);术后2个月CT或MR复查,并测量肿瘤大小,按改良的实体瘤疗效评价(RECIST)标准评价:部分缓解29.63%(16/54),稳定57.41%(31/54),进展12.96%(7/54)。结论 KMG栓塞治疗HCC是安全的,近期疗效显著。

Objective To investigate the short-term efficacy of embolization with sodium alginate microspheres(KMG) for treatment of hepatocellular carcinoma(HCC). Methods Between Jul 2009 and Nov 2012, Fifty-four patients with HCC underwent TACE/TAE with KMG. Tumor responses, complications and adverse reactions related to embolization were analyzed. Results TACE/TAE was successfully accomplished in all patients. The common adverse reactions after embolization including abdominal pain(36/54, 66.67%), fever(30/54, 55.56%), nausea and vomiting(15/54, 27.78%). No severe complication occurred. Twenty-two HCC patients also had arterioportal shunts(APS) or arteriovenous shunts(AVS). According to modified response evaluation criteria in solid tumors(RECIST) criteria, the two months follow-up results are as follows: 29.63%(16/54) with partial response, 57.41%(31/54) with stable disease, and 12.96%(7/54) with progressive disease, respectively. Conclusions Embolization with using of KMG is a safe and feasible treatment for HCC with remarkable shortterm efficacy.